Literature DB >> 32609095

The multifaceted nature of HIV latency.

Caroline Dufour1, Pierre Gantner1, Rémi Fromentin2, Nicolas Chomont1,2.   

Abstract

Although antiretroviral therapies (ARTs) potently inhibit HIV replication, they do not eradicate the virus. HIV persists in cellular and anatomical reservoirs that show minimal decay during ART. A large number of studies conducted during the past 20 years have shown that HIV persists in a small pool of cells harboring integrated and replication-competent viral genomes. The majority of these cells do not produce viral particles and constitute what is referred to as the latent reservoir of HIV infection. Therefore, although HIV is not considered as a typical latent virus, it can establish a state of nonproductive infection under rare circumstances, particularly in memory CD4+ T cells, which represent the main barrier to HIV eradication. While it was originally thought that the pool of latently infected cells was largely composed of cells harboring transcriptionally silent genomes, recent evidence indicates that several blocks contribute to the nonproductive state of these cells. Here, we describe the virological and immunological factors that play a role in the establishment and persistence of the pool of latently infected cells and review the current approaches aimed at eliminating the latent HIV reservoir.

Entities:  

Mesh:

Year:  2020        PMID: 32609095      PMCID: PMC7324199          DOI: 10.1172/JCI136227

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  198 in total

1.  Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy.

Authors:  Timothy J Henrich; Kristen S Hobbs; Emily Hanhauser; Eileen Scully; Louise E Hogan; Yvonne P Robles; Kaitlyn S Leadabrand; Francisco M Marty; Christine D Palmer; Stephanie Jost; Christian Körner; Jonathan Z Li; Rajesh T Gandhi; Ayad Hamdan; Jeremy Abramson; Ann S LaCasce; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

2.  Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy.

Authors:  Carolina Gutiérrez; Sergio Serrano-Villar; Nadia Madrid-Elena; Maria J Pérez-Elías; Maria Elena Martín; Coral Barbas; Javier Ruipérez; Eduardo Muñoz; Maria Angeles Muñoz-Fernández; Trevor Castor; Santiago Moreno
Journal:  AIDS       Date:  2016-06-01       Impact factor: 4.177

3.  Infrequent HIV Infection of Circulating Monocytes during Antiretroviral Therapy.

Authors:  Marta Massanella; Wendy Bakeman; Pasiri Sithinamsuwan; James L K Fletcher; Nitiya Chomchey; Somporn Tipsuk; Thep Chalermchai; Jean-Pierre Routy; Jintanat Ananworanich; Victor G Valcour; Nicolas Chomont
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

4.  High proportion of PD-1-expressing CD4+ T cells in adipose tissue constitutes an immunomodulatory microenvironment that may support HIV persistence.

Authors:  Abderaouf Damouche; Guillaume Pourcher; Valérie Pourcher; Stéphane Benoist; Elodie Busson; Jean-Jacques Lataillade; Mélanie Le Van; Thierry Lazure; Julien Adam; Benoit Favier; Bruno Vaslin; Michaela Müller-Trutwin; Olivier Lambotte; Christine Bourgeois
Journal:  Eur J Immunol       Date:  2017-08-28       Impact factor: 5.532

5.  HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells.

Authors:  Leonard Chavez; Vincenzo Calvanese; Eric Verdin
Journal:  PLoS Pathog       Date:  2015-06-11       Impact factor: 6.823

6.  Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.

Authors:  Richard Brad Jones; Rachel O'Connor; Stefanie Mueller; Maria Foley; Gregory L Szeto; Dan Karel; Mathias Lichterfeld; Colin Kovacs; Mario A Ostrowski; Alicja Trocha; Darrell J Irvine; Bruce D Walker
Journal:  PLoS Pathog       Date:  2014-08-14       Impact factor: 6.823

7.  HIV-Specific CD8+ T Cells Exhibit Reduced and Differentially Regulated Cytolytic Activity in Lymphoid Tissue.

Authors:  Morgan A Reuter; Perla M Del Rio Estrada; Marcus Buggert; Constantinos Petrovas; Sara Ferrando-Martinez; Son Nguyen; Alberto Sada Japp; Yuria Ablanedo-Terrazas; Amaranta Rivero-Arrieta; Leticia Kuri-Cervantes; Heidi M Gunzelman; Emma Gostick; David A Price; Richard A Koup; Ali Naji; David H Canaday; Gustavo Reyes-Terán; Michael R Betts
Journal:  Cell Rep       Date:  2017-12-19       Impact factor: 9.423

8.  Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation.

Authors:  Mila Jankovic; Michel C Nussenzweig; Lillian B Cohn; Israel T da Silva; Renan Valieris; Amy S Huang; Julio C C Lorenzi; Yehuda Z Cohen; Joy A Pai; Allison L Butler; Marina Caskey
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

9.  Entry of Polarized Effector Cells into Quiescence Forces HIV Latency.

Authors:  Curtis Dobrowolski; Saba Valadkhan; Amy C Graham; Meenakshi Shukla; Angela Ciuffi; Amalio Telenti; Jonathan Karn
Journal:  mBio       Date:  2019-03-26       Impact factor: 7.867

10.  New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.

Authors:  C Korin Bullen; Gregory M Laird; Christine M Durand; Janet D Siliciano; Robert F Siliciano
Journal:  Nat Med       Date:  2014-03-23       Impact factor: 53.440

View more
  15 in total

Review 1.  Lessons for Understanding Central Nervous System HIV Reservoirs from the Last Gift Program.

Authors:  Patricia K Riggs; Antoine Chaillon; Guochun Jiang; Scott L Letendre; Yuyang Tang; Jeff Taylor; Andrew Kaytes; Davey M Smith; Karine Dubé; Sara Gianella
Journal:  Curr HIV/AIDS Rep       Date:  2022-10-19       Impact factor: 5.495

Review 2.  The state of latency in microbial pathogenesis.

Authors:  Liise-Anne Pirofski; Arturo Casadevall
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

Review 3.  So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.

Authors:  Adam J Kleinman; Ivona Pandrea; Cristian Apetrei
Journal:  Viruses       Date:  2022-01-12       Impact factor: 5.048

4.  Editorial: Exploring Novel Approaches to Eliminate HIV Reservoirs to Achieve a Cure for HIV.

Authors:  Renée M van der Sluis; Andrés Finzi; Matthew S Parsons
Journal:  Front Cell Infect Microbiol       Date:  2021-02-25       Impact factor: 5.293

5.  A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir.

Authors:  Claire N Levy; Sean M Hughes; Pavitra Roychoudhury; Daniel B Reeves; Chelsea Amstuz; Haiying Zhu; Meei-Li Huang; Yulun Wei; Marta E Bull; Noah A J Cassidy; Jan McClure; Lisa M Frenkel; Mars Stone; Sonia Bakkour; Elizabeth R Wonderlich; Michael P Busch; Steven G Deeks; Joshua T Schiffer; Robert W Coombs; Dara A Lehman; Keith R Jerome; Florian Hladik
Journal:  Cell Rep Med       Date:  2021-04-12

Review 6.  SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise.

Authors:  Ralf Duerr; Keaton M Crosse; Ana M Valero-Jimenez; Meike Dittmann
Journal:  Microorganisms       Date:  2021-06-27

Review 7.  HIV-1 persistence in the CNS: Mechanisms of latency, pathogenesis and an update on eradication strategies.

Authors:  Shilpa Sonti; Adhikarimayum Lakhikumar Sharma; Mudit Tyagi
Journal:  Virus Res       Date:  2021-07-24       Impact factor: 3.303

8.  CPI-637 as a Potential Bifunctional Latency-Reversing Agent That Targets Both the BRD4 and TIP60 Proteins.

Authors:  Tengyi Zheng; Pei Chen; Yifan Huang; Jiayin Qiu; Chenliang Zhou; Ziyao Wu; Lin Li
Journal:  Front Cell Infect Microbiol       Date:  2021-07-19       Impact factor: 5.293

Review 9.  HIV-1 and human genetic variation.

Authors:  Paul J McLaren; Jacques Fellay
Journal:  Nat Rev Genet       Date:  2021-06-24       Impact factor: 53.242

10.  Alprazolam Prompts HIV-1 Transcriptional Reactivation and Enhances CTL Response Through RUNX1 Inhibition and STAT5 Activation.

Authors:  Angel Lin; Weam Othman Elbezanti; Alexis Schirling; Adel Ahmed; Rachel Van Duyne; Simon Cocklin; Zachary Klase
Journal:  Front Neurol       Date:  2021-07-22       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.